U.S. Online Retail and Ecommerce Stock News

NasdaqCM:SEED 1 Year Share Price vs Fair Value Explore Origin Agritech's Fair Values from the Community and select...

NasdaqCM:ESLA 1 Year Share Price vs Fair Value Explore Estrella Immunopharma's Fair Values from the Community and...

NasdaqCM:MDRR 1 Year Share Price vs Fair Value Explore Medalist Diversified REIT's Fair Values from the Community and...

NasdaqCM:BWB 1 Year Share Price vs Fair Value Explore Bridgewater Bancshares's Fair Values from the Community and...

NasdaqGS:IRWD 1 Year Share Price vs Fair Value Explore Ironwood Pharmaceuticals's Fair Values from the Community and...

NasdaqGS:ATLC 1 Year Share Price vs Fair Value Explore Atlanticus Holdings's Fair Values from the Community and select...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

NYSE:CCL 1 Year Share Price vs Fair Value Explore Carnival Corporation &'s Fair Values from the Community and select...

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...

Earlier this month, Revvity unveiled its pHSense™ reagents, a new technology developed to improve the efficiency and accuracy of internalization studies in drug discovery, specifically for G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs). This platform aims to address current challenges in high-throughput screening and is positioned to meet rising demand for advanced tools in oncology and precision medicine research workflows. We'll examine how the launch of pHSense™...

Earlier this month, MarketAxess Holdings reported strong second quarter results with revenue rising to US$219.46 million and multiple enhancements to its electronic trading protocols, while also announcing a quarterly dividend and signaling readiness for merger and acquisition opportunities. CEO Christopher Concannon highlighted both a robust balance sheet and new executive capacity as key enablers for potential M&A, suggesting an active approach to future growth initiatives beyond...

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...

Yum! Brands, Inc. reported its second quarter 2025 earnings on August 5, revealing US$1.93 billion in revenue and US$374 million in net income, both higher than the same period last year. While the quarter showed stronger sales, net income for the first half of 2025 was US$628 million, down from US$681 million a year earlier, reflecting mixed profitability trends despite revenue growth. We'll now explore how these mixed profit and revenue results may affect Yum! Brands' ongoing investment...

Earlier this month, Quanta Services completed a US$1.5 billion multi-tranche senior notes offering with maturities spanning 2028, 2031, and 2035, intending to use the proceeds to repay existing borrowings under its commercial paper program and senior credit facility. By extending its debt maturity profile and locking in fixed interest rates, Quanta Services could see changes in its financial flexibility and interest expenses, influencing its future capital allocation decisions. We'll explore...

TG Therapeutics recently reported strong second quarter results, with US$141.15 million in revenue and a sharp rise in net income, and raised its full-year 2025 revenue guidance to approximately US$585 million. The company also filed multiple shelf registrations totaling up to US$139.45 million, including an ESOP-related offering, indicating preparations for potential future capital needs alongside improving financial performance. We’ll now explore how the raised annual guidance and robust...

Fastly announced its second-quarter 2025 earnings, updated guidance, key executive appointments, including a new CFO, and a shelf registration for US$12.76 million in Class A shares for an employee stock plan. The consolidation of marketing and revenue under a new President, alongside leadership changes and fresh capital strategies, marks an important expansion of operational focus and corporate direction. We'll explore how Fastly's leadership realignment and updated guidance may influence...

GRAIL, Inc. reported second quarter and six-month results for the period ended June 30, 2025, showing sales of US$34.38 million and US$63.51 million respectively, with net losses narrowing substantially from the prior year and impairment charges decreasing to US$28 million from a very large US$1.42 billion a year earlier. This sharp reduction in both net loss and impairment charges points to improved operational discipline and financial stability at the company. We'll explore how GRAIL's...

Earlier this past week, Kymera Therapeutics announced positive results from its first KT-621 clinical trial, which delivered strong efficacy and a placebo-like safety profile, alongside new collaborations with Gilead and Sanofi and disclosure of a cash reserve near US$1 billion by July's end. An important takeaway is that Kymera's strengthened pipeline through high-profile partnerships and a substantial cash runway may provide meaningful support for future research and development...

Earlier this month, Wix.com reported strong quarterly earnings, raised its full-year revenue guidance, and expanded its share buyback authorization by US$200 million to US$600 million, while also launching new financial services products for small businesses in the U.S. By integrating business checking and cash advance services directly into its platform, Wix.com is seeking to make financial management and growth capital more accessible for its business customers. We'll explore how the...

Viridian Therapeutics recently reported its second quarter and six-month earnings for 2025, revealing a wider net loss of US$100.74 million and US$187.65 million respectively, both larger than the losses reported a year earlier. Alongside these results, the company filed a new shelf registration to potentially offer 11,228,650 shares, which may reflect ongoing capital needs and could influence future dilution concerns. We'll examine how the combination of larger losses and the shelf...

Formula One Group reported its second quarter 2025 earnings on August 7, showing sales of US$1.20 billion and net income of US$382 million, both up sharply from a year earlier. This marks a very large year-over-year increase in net income, highlighting the impact of strong commercial partnerships and expanding media revenues. We'll explore how this significant boost in quarterly profits could influence analyst expectations about Formula One Group's earnings trajectory and risk profile. These...

Abbott Laboratories recently reported strong financial results, achieving 18% annual earnings per share growth over the past three years and a 5.9% rise in revenue, while insider ownership was valued at US$1.1 billion. This combination of robust performance and significant insider confidence underlines stability in the company's leadership and alignment with shareholder interests. We'll explore how Abbott's large insider ownership and earnings momentum may shape its investment narrative...

BlackLine recently announced leadership changes, with founder Therese Tucker transitioning from Co-CEO to Founder and Owen Ryan assuming the CEO role, alongside board updates and the appointment of a new Lead Independent Director following the release of its second quarter earnings results. An important insight is that these developments occurred just as BlackLine reported higher year-over-year revenue but saw a pronounced decline in net income and earnings per share, reflecting operational...